Boston Scientific stock remains under close watch as the company's fair value target holds steady at $126.48 per share. This reflects analysts' continued confidence following the latest results. While ...

Boston Scientific BSX posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior-year period. The increase was mainly ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion. The medical technology giant reported ...

Boston Scientific (NYSE:BSX) traded higher on Wednesday after the MedTech giant exceeded Street forecasts with its Q3 2025 results and boosted its full-year outlook following better-than-expected ...

Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second quarter, when sales rose more than 22%. Urology led the gains, up 28% year ...

Boston Scientific continues to build on its significant Minnesota footprint. The Massachusetts-based medical device giant on Monday opened an Arbor Lakes facility in Maple Grove. The new ...

On Friday, Boston Scientific Corporation announced an agreement to acquire Nalu Medical, a medical technology company focusing on chronic pain. Boston Scientific has been an investor in Nalu Medical ...

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following ...

The U.S. Food and Drug Administration is warning patients and doctors about possible issues seen with Boston Scientific heart devices. The FDA issued alerts on Aug. 6 about the Marlboro-based ...

WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. Today in History ...